Clinical trials · Texas
Age-Related Macular Degeneration clinical trials in Texas
We’re tracking 40 recruiting age-related macular degeneration studies with a site in Texas — including Phase 1, Phase 1/Phase 2, Phase 2, Phase 2/Phase 3, Phase 3 and Phase 4 studies, each written for real people, not researchers.
Recruiting studies in Texas
- NCT07614776RecruitingPhase 3
New Eye Injection Treatment for Age-Related Macular Degeneration
This study tests whether a new eye injection called ABP 938 works as well as or better than the current standard treatment (Eylea) for wet age-related macular degeneration—a condition that causes vision loss in the center of your sight. You would receive injections into your eye every month for a year.
Arlington, TexasAges 50 years+ - NCT07440225RecruitingPhase 2/Phase 3
Testing a new drug for wet macular degeneration
This trial tests a new medicine called EYE201/MK-8748 for people who have wet age-related macular degeneration (a condition where abnormal blood vessels grow under the retina). It's for those who haven't had treatment before and were diagnosed recently.
Abilene, TexasAges 50 years+ - NCT07441642RecruitingPhase 2
Study of FWY003 for geographic atrophy in age-related macular degeneration
This trial tests an investigational drug FWY003 against a placebo to see if it can slow or stop the progression of geographic atrophy, a form of advanced age-related macular degeneration that causes vision loss.
Bellaire, TexasAges 50 years+ - NCT05197270RecruitingPhase 1/Phase 2
Gene therapy for wet age-related macular degeneration
This study tests a new gene therapy called 4D-150 for people with wet age-related macular degeneration (AMD). It aims to reduce the need for frequent anti-VEGF injections by delivering a long-lasting treatment into the eye.
Austin, TexasAges 50 years+ - NCT07770828RecruitingPhase 3
Gene therapy for advanced dry age-related macular degeneration
This trial tests an experimental gene therapy, OCU410, for people with geographic atrophy, an advanced form of dry AMD that causes blind spots in the center of vision. The study aims to see if this treatment can slow down the progression of the disease and help preserve remaining vision.
McAllen, TexasAges 55 years+ - NCT07007065RecruitingPhase 3
Study of a gene therapy for wet age-related macular degeneration
This trial tests a one-time gene therapy injection for wet AMD that may reduce the need for regular eye injections. It is for people who have already responded to anti-VEGF injections but want a longer-lasting treatment.
Abilene, TexasAges 50 years+ - NCT06541704RecruitingPhase 3
Study of pozelimab with cemdisiran for geographic atrophy
This trial tests a combination of two study drugs (pozelimab and cemdisiran) given as a shot under the skin to slow the progression of geographic atrophy, a type of advanced dry age-related macular degeneration that causes blind spots in central vision.
Abilene, TexasAges 50–85 - NCT06662162Recruiting
Microcurrent therapy for dry age-related macular degeneration
This trial tests a new type of electrical stimulation, called microcurrent therapy, to see if it can help people with a certain form of age-related macular degeneration (AMD) that is not the "wet" kind. The treatment is delivered through an eye patch-like device and may slow vision loss or improve function.
Fort Worth, TexasAges 60 years+ - NCT04853251RecruitingPhase 4
Study of corneal cells after a ranibizumab eye implant
This trial checks how well corneal endothelial cells (cells that help keep the cornea clear) do in people with neovascular age-related macular degeneration (nAMD) who are treated with a port-delivery implant that releases ranibizumab. It also helps doctors understand whether this method changes corneal health and stays safe while controlling the eye disease.
Amarillo, TexasAges 50 years+ - NCT07496567RecruitingPhase 2/Phase 3
Study of EYE201 for wet age-related macular degeneration
This trial tests a new medicine, EYE201, for people with wet age-related macular degeneration (AMD) that has not been treated before. The study will see if this drug can help improve vision and slow down vision loss.
Bellaire, TexasAges 50 years+ - NCT05986864RecruitingPhase 1/Phase 2
Gene therapy injection for wet AMD
This study tests a new gene therapy injection called SKG0106 for people with wet AMD. The treatment is given as an injection into the eye and aims to reduce the need for frequent anti-VEGF shots.
Katy, TexasAges 50 years+ - NCT07516132RecruitingPhase 3
Long-term safety study of axitinib implant for wet macular degeneration
This study follows people who completed an earlier 2-year trial of OTX-TKI, a small implant placed in the eye to treat wet age-related macular degeneration (a condition causing vision loss). Researchers want to make sure the treatment remains safe over time.
Austin, TexasAges 50 years+ - NCT07215390RecruitingPhase 2
Study of APL-3007 plus Syfovre for geographic atrophy
This trial tests whether a new drug called APL-3007, when added to your current Syfovre treatment, can slow the progression of geographic atrophy (an advanced form of dry age-related macular degeneration). It's for people who have already been on Syfovre for at least 6 months.
Bellaire, TexasAges 60 years+ - NCT07392255RecruitingPhase 1/Phase 2
Testing CTx001 for geographic atrophy (GA) in AMD
This trial is testing a new treatment called CTx001 for people with geographic atrophy (GA), a late stage of dry age-related macular degeneration (AMD). The goal is to see if the treatment is safe and can slow vision loss.
Dallas, TexasAges 55 years+ - NCT03683251RecruitingPhase 3
Extension study for a refillable eye implant plus ranibizumab
This trial studies whether continuing treatment with a refillable eye implant (Port Delivery System) and ranibizumab injection helps control a specific type of wet macular degeneration. It’s mainly for people who already finished an earlier related study and are able to keep up with frequent eye checks and procedures.
Arlington, TexasAges 50 years+ - NCT05210803Enrolling by invitationPhase 2
Long-term safety follow-up for wet AMD treatment
This study is a follow-up for people who have already received an injection of RGX-314 for wet age-related macular degeneration (AMD) in an earlier trial. It looks at how the treatment works over a longer time and any long-term effects.
The Woodlands, TexasAges Any age - NCT06990269RecruitingPhase 2
Study of ADX-038 for geographic atrophy in dry AMD
This trial tests an investigational drug (ADX-038) for people with geographic atrophy, a form of advanced dry age-related macular degeneration. The drug is given as an injection into the eye, and the study checks if it can slow down the growth of GA spots.
McAllen, TexasAges 60 years+ - NCT07630649RecruitingPhase 2
Gene therapy for wet age-related macular degeneration in second eye
This study tests a one-time gene therapy injection (ixoberogene soroparvovec) in the second eye of people with wet age-related macular degeneration who have already responded well to anti-VEGF injections. The goal is to see if this gene therapy can help preserve or improve vision in that eye.
The Woodlands, TexasAges 50 years+ - NCT07144137Recruiting
Observation study for geographic atrophy progression
This study observes how geographic atrophy (an advanced form of dry age-related macular degeneration) changes over a short period. If you have this condition in both eyes and meet certain vision and eye health criteria, you may be able to join this non-treatment study to help researchers learn more about the disease.
Dallas, TexasAges 55 years+ - NCT06659445RecruitingPhase 2
Study of ONL1204 for geographic atrophy in dry AMD
This study tests an investigational medicine called ONL1204 given as an injection into the eye for people with a form of advanced dry age-related macular degeneration called geographic atrophy. The goal is to see if it can slow vision loss.
Austin, TexasAges 55 years+ - NCT07482176RecruitingPhase 3
Gene therapy trial for wet age-related macular degeneration
This trial tests a one-time gene therapy injection (IXO-vec) for people with wet age-related macular degeneration (nAMD). It aims to reduce the need for frequent eye injections by helping the eye make its own medicine to block the growth of harmful blood vessels.
Arlington, TexasAges 50 years+ - NCT03178149RecruitingPhase 1
Study of a new eye treatment for dry macular degeneration
This Phase 1 trial tests the safety and side effects of ASP7317 in older adults whose central vision is worsening from dry age-related macular degeneration (geographic atrophy). If you qualify, you would receive treatment in the study eye and be closely monitored for about a year.
Dallas, TexasAges 50 years+ - NCT07160179RecruitingPhase 1/Phase 2
Study of an eye injection for geographic atrophy
This study tests a new medicine (ABBV-6628) given as an injection into the eye to see how well it works and how it moves through the body for people with geographic atrophy (an advanced form of dry age-related macular degeneration). It may help slow vision loss from this condition.
Abilene, TexasAges 50 years+ - NCT05438732Recruiting
Test of an implanted eye device plus vision training for AMD
This study tests a device that is surgically implanted in the eye of people with late-stage age-related macular degeneration (AMD). It also uses vision training with a telescope-like tool to see if the treatment can improve day-to-day vision.
Houston, TexasAges 65 years+
Age-Related Macular Degeneration trials by city in Texas
Where these studies are running in Texas
Institutions with a site for the recruiting age-related macular degeneration studies listed above.
- Retina Consultants of Texas · 14 studies
- Austin Retina Associates · 10 studies
- Texas Retina Associates · 7 studies
- Valley Retina Institute · 6 studies
- Austin Clinical Research, LLC · 5 studies
- Retina Foundation of the Southwest · 5 studies
- Retina Center of Texas · 4 studies
- Retina Research Institute of Texas · 4 studies
What taking part in a age-related macular degeneration study involves
A screening visit first
Before anything else, the study team checks whether you fit — usually a visit with some tests. You can stop at any point, and screening is typically free.
Care at a nearby site
Study visits happen at a clinic or hospital taking part. Many studies cover the cost of the study treatment and related visits, and some reimburse travel.
You stay in control
Taking part is voluntary and you can leave a study at any time, for any reason, without affecting your regular care.
The team decides eligibility
Our fit check is a helpful first read, not a decision. The study team makes the final call after reviewing your health history.
Age-Related Macular Degeneration trials in other states
Common questions
- Are there age-related macular degeneration clinical trials in Texas?
- Yes. We're currently tracking 40 recruiting age-related macular degeneration studies with a site in Texas, each rewritten in plain language so you can see what it's testing and who it's for.
- How do I find out if I qualify for a age-related macular degeneration study in Texas?
- Each study lists its eligibility rules — age, diagnosis, prior treatments. On every trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Do I have to live in Texas to take part?
- Not necessarily. These studies have a site in Texas, but eligibility is about your health, not your address — some people travel to take part, and a few studies reimburse travel. The study team can tell you what's required.
- Does it cost anything to join a age-related macular degeneration trial?
- Using Clin2 is always free. Many trials cover the study treatment and related visits; some reimburse travel. The study team explains exactly what's covered before you decide.
Not the right time?
New age-related macular degeneration studies open in Texas regularly. Set up a health profile and we’ll quietly watch for studies that fit you and email you when one opens.
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.